Another combination treatment with panobinostat and letrozole inhibited aromatase expression in hormone-responsive breast cancer cells [74], suggesting that these combination therapies are likely to target hormone receptor-positive/aromatase-positive breast cancer. Here, CYP19A1 is linked to breast cancer.